1
As a practice nurse, you know the importance of protecting your most vulnerable patients.
Prevenar 13 is well established for the protection of infants (>6 weeks) against pneumococcal
disease. It’s not just babies who can be vaccinated though; help protect all your patients who are at
increased risk. 1 Adults may need protection too, help protect them today.
The Immunisation Handbook recommends that all patients at highest risk of pneumococcal disease
(Category A) receive Prevenar 13. Refer to the Handbook for details. 2
To learn more about Prevenar 13, call 1800 675 229
PBS Information: This product is listed on the National Immunisation Programme (NIP)
for children only and is not listed on the PBS. Refer to the NIP Schedule.
BEFORE PRESCRIBING, PLEASE REVIEW THE PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT IN THIS PUBLICATION.
Limited safety and immunogenicity data on PREVENAR 13 are available for patients with sickle cell disease, allogeneic haematopoietic stem cell transplant, or HIV infection, and are not available for other immunocompromised patient groups. Efficacy/effectiveness
has not been established. Vaccination should be considered on an individual basis. Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive
therapy may have a reduced antibody response to PREVENAR 13. Immunisation schedules for PREVENAR 13 should be based on official recommendations. References: 1. PREVENAR 13 ® Approved Product
Information. 2. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook 10th Ed (2017 Update). Canberra: Australian Government Department of Health, 2017. Available
at www.immunise.health.gov.au. Accessed August 2017. ®Registered trademark. Pfizer Australia Pty Limited, 38–42 Wharf Road, West Ryde, NSW 2114. PP-PNA-AUS-0103. PFAPRE2413FP/NR. 09/17. GHG.